ABVC Biopharma Inc (ABVC) USD0.001

Sell:$2.84Buy:$2.95$0.02 (0.69%)

Prices delayed by at least 15 minutes
Sell:$2.84
Buy:$2.95
Change:$0.02 (0.69%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.84
Buy:$2.95
Change:$0.02 (0.69%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.

Key people

Eugene Jiang
Chairman of the Board, Chief Business Officer
Uttam Yashwant Patil
Chief Executive Officer, Interim Chief Financial Officer
Tsung-Shann Jiang
Chief Scientific Officer, Chief Strategy Officer, Director
Chang-Jen Jiang
Director
Shuling Jiang
Director
Tsang Ming Jiang
Director
Yen-Hsin Chou
Independent Director
Yu- Min Chung
Independent Director
Click to see more

Key facts

  • Shares in issue
    24.27m
  • EPIC
    ABVC
  • ISIN
    US00091F3047
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $68.51m
  • Employees
    16
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.